Last reviewed · How we verify
Fentanyl ev
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Acute and chronic pain management, Perioperative analgesia and sedation, Palliative care.
At a glance
| Generic name | Fentanyl ev |
|---|---|
| Also known as | Fentanest |
| Sponsor | Azienda Sanitaria dell'Alto Adige |
| Drug class | Synthetic opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain management, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Fentanyl activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. The 'ev' designation likely refers to an intravenous formulation. It is a potent synthetic opioid approximately 50-100 times more potent than morphine.
Approved indications
- Acute and chronic pain management
- Perioperative analgesia and sedation
- Palliative care
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea and vomiting
- Dizziness
- Constipation
Key clinical trials
- Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope (PHASE4)
- Sublingual Versus Endovenous Fentanyl for Pain Treatment in Trauma Patients in the Emergency Room (PHASE4)
- Continuous Infusion of Fentanyl in Preterm on MV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |